Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.

You may also be interested in...



Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III

H. Lundbeck and Takeda Pharmaceutical have initiated Phase III trials of their novel mood and anxiety disorders candidate Lu AA21004 roughly four months after inking a co-development deal, the firms announced Dec. 18

Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III

Milestone garners Danish firm $40 million four months into collaboration with Takeda.

Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III

Milestone garners Danish firm $40 million four months into collaboration with Takeda.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel